Vinay, Keshavamurthy; Cazzaniga, Simone; Amber, Kyle T; Feldmeyer, Laurence; Borradori, Luca (2018). Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center. Journal of the American Academy of Dermatology, 78(4), pp. 806-808. Elsevier 10.1016/j.jaad.2017.11.024
|
Text
1-s2.0-S0190962217326890-main.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (200kB) | Preview |
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Cazzaniga, Simone, Feldmeyer, Laurence, Borradori, Luca |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0190-9622 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
05 Mar 2018 15:14 |
Last Modified: |
05 Dec 2022 15:10 |
Publisher DOI: |
10.1016/j.jaad.2017.11.024 |
PubMed ID: |
29146127 |
Uncontrolled Keywords: |
Complete remission First line Pemphigus Relapse Rituximab |
BORIS DOI: |
10.7892/boris.110145 |
URI: |
https://boris.unibe.ch/id/eprint/110145 |
Actions (login required)
 |
Edit item |